Cardiogen

Grade D: Preclinical or anecdotal only

TL;DR: Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed within the Khavinson bioregulator program in Russia. The only citation in the input dataset is a single preclinical study in senescent rats examining effects on a transplanted sarcoma line, that is not a cardiovascular efficacy study and is not applicable to human cardiac health. Secondary literature sources describe some small clinical observations (blood pressure variability, post-infarction rehabilitation add-on), but these originate almost exclusively from a single Russian research group and have not been independently replicated in Western, Japanese, or other non-Russian settings to a standard that would satisfy regulatory evidentiary thresholds. No peer-reviewed, placebo-controlled human trial of Cardiogen for any indication has been identified. The proposed grade of D is accurate; the evidence base does not support upgrading it.

Key Takeaways

Grade D: Preclinical or anecdotal only
Not FDA approved: Not approved; available as a research compound and, in some markets, as an over-the-counter bioregulator supplement; no FDA regulatory review on record.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

Proposed to act as a short peptide signal that modulates transcription factor activity in cardiomyocytes, putatively influencing gene expression patterns associated with cardiac cell differentiation and repair.

Evidence

Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed within the Khavinson bioregulator program in Russia. The only citation in the input dataset is a single preclinical study in senescent rats examining effects on a transplanted sarcoma line, that is not a cardiovascular efficacy study and is not applicable to human cardiac health. Secondary literature sources describe some small clinical observations (blood pressure variability, post-infarction rehabilitation add-on), but these originate almost exclusively from a single Russian research group and have not been independently replicated in Western, Japanese, or other non-Russian settings to a standard that would satisfy regulatory evidentiary thresholds. No peer-reviewed, placebo-controlled human trial of Cardiogen for any indication has been identified. The proposed grade of D is accurate; the evidence base does not support upgrading it.

Safety and risks

No published human safety data exists for Cardiogen specifically. Systemic toxicology and pharmacokinetic profiles in humans are not publicly documented. Because the compound derives from the Khavinson peptide bioregulator tradition, it shares the general limitation of that literature: studies have been small, open-label, conducted by the originating group, and not subjected to independent safety monitoring. Oral administration is often assumed to be low-risk due to rapid peptide hydrolysis, but this assumption has not been formally validated for this compound. Injectable forms carry the standard risks of parenteral administration without clinical safety data to characterize adverse event frequency or severity.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. (2009) other

Cardiogen is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).